Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!

AusCann Cannabis Stocks

AusCann Cannabis Stock (ACNNF)

[stock_market_widget type="spark" symbol="ACNNF" template="line" color="green"]

AusCann is a pharmaceutical company focusing on pre-clinical drug candidate development and production. They focus on cannabinoid drug candidates and are located in Australia.

Is AusCann Cannabis Stock (ACNNF) a strong BUY and HOLD?

ACNNF Fundamental Analysis

Profile

HQ: Perth, Western Australia
Founded: 2013
Symbol: ACNNF (OTC), AC8 (ASX)

FocusStrong 

Producing and selling medical cannabis to patients in Australia, and later the world. They are focused on creating cannabis treatments for pain, plus other conditions.  This is a $9 billion market in Australia alone. Many investors know of them from their relationship (now closed) with Canopy Growth. 

Size: Neutral

Market Cap: $31.6 mil
Enterprise Value: $17.94 mil
Number of Employees: 32

Markets: Neutral

Primary: Initially Australia (and Tasmania), where medical MJ is legal, but adult use is not (nor expected soon). Also Chile, through a partnership

Secondary: MA, CT, PA, and CA in the near future, Canada

Subsidiaries, Interests:
DayaCann (Chile), Yarra Glen Vineyards Holdings, ACN 096 717 458 Pty Ltd, Australian Commercial Wines Pty Ltd.
 

Operations: Neutral

Cultivation: None
Current production: Drug development focusing on their first product, for chronic pain, a dry powder 50:50 ratio of THC:CBD in a hard shell capsule formulation.

Distribution: Initial sales of their capsules are currently being ordered.
Direct sales: Yes

Store networks: Has an agreement with the leading Australian pharmacy API to distribute medical cannabis through nationwide pharmacy networks

Integration/Diversification: 
Vertically integrated: Yes
Horizontally diversified: No

Financials: Weak

Revenue (2019): $671,000
Shares Outstanding (diluted): 317 million
Return on Equity: -18.55%

Management: Neutral

CEO: Nick Woolf
CFO: Quentin Megson
Director: Max Johnston
Director: Bruce McHarrie
Director: Krista Bates

Old CEO Ido Kanyon stepped down in May. Much of the Board also turned over this year. The end of their relationship with Canopy late last year also shifted the directors. There has been a LOT of turnover for AusCann.

Branding: Neutral

Most of their drugs cover anti-convulsion, anti-inflammatory, anti-nausea, glaucoma, pain management, and appetite stimulation areas. They have not branded any of their drug candidates yet as none are approved.

Valuation: Weak

Current share price: $0.095
Price to Sales: 13,190
52 week low/high: $0.067-$0.25
EV/Revenue: 5,600
Price/Book: 1.22

Financing: Strong

AusCann has no debt but is burning cash fast, typical of most pharma companies undergoing drug development. Clinical trials are expensive, and they have over $34 million to pay for the next few (company net assets were reported at $34.37 million). They reported $7 million in losses last fiscal year. 

 

ACNNF Technical Analysis

Should I buy AusCann Cannabis Stock?

Is AusCann Cannabis Stock (ACNNF) a Buy?

Follow Stephen Goldman as he investigates the differences between common momentum-based indicators such as the MACD and KST (Know Sure Thing) while learning how to spot opportunities to buy and sell AusCann.

Remember sound cannabis stock trading strategies include both Fundamental Analysis and Technical Analysis.

[stock_market_widget type="leaderboard" symbol="ACNNF" template="basic" color="default"]

Bottom Line: Is AusCann Cannabis Stock (ACNNF) a Buy?

Recommendation: Weak

Is AusCann Cannabis Stock (ACNNF) a Buy?

AusCann is often referred to as having the lead position in the Australian cannabis industry. They used to have Canopy Growth as 10% investors but now Canopy has been replaced by local Australian Merchant Capital.

From a licensing perspective, they are ahead of other competitors in Australia. They can produce, sell import, and export. They may have a strong position if they can deliver on production and distribution. It’s a big unknown.

The company has reported only $671k in revenue for the year ending Dec 2019. This revenue was not based on sales as none of their drug candidates are approved. The drug furthest along is their 1:1 THC: CBD capsule for chronic pain indications. This would be a large market to enter (Pain drugs) but they are still a way away from sales for this drug.

Its price to sales ratio is an astronomical 13,000 and they EV/Revenue is 5,600. We don’t typically see values this high in our analyses (remember lower is better here).

They do have a partnership with Tasmanian Alkaloids Pty Ltd. to distribute medical cannabis in Tasmania. TasAlk produces 40% of the world’s alkaloid raw material and a partnership with DayaCann, the only licensed medicinal cannabis grower in Chile. These deals extend their reach internationally.

For all the reasons above, we rate this stock as Weak. Perhaps in a few more years, their drugs will be closer to approvals and they’ll be closer to revenue. Until then, expect dilution if you’re a shareholder.

For all the reasons above, we rate this stock as Weak but check out our other featured companies for many other winners in the cannabis and hemp industry.

[stock_market_widget type="combo" symbol="ACNNF" template="tablechart" color="default" fields="virtual.symbol,virtual.name,quote.regularMarketPrice,quote.regularMarketChange,quote.regularMarketChangePercent" chart="line" range="1y" interval="1d" line-color="rgb(0, 128, 0)"]

Trulieve Opens Two Medical Cannabis Dispensaries in West Virginia

Trulieve Opens Two Medical Cannabis Dispensaries in West Virginia South Charleston and Parkersburg locations both opening on Saturday, May 21 at 10 a.m. Trulieve Cannabis  (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States, today...

Cresco Labs Granted $38 Million Tax Break for NY Cannabis Facility

Cresco Labs Granted $38 Million Tax Break for NY Cannabis Facility Ulster County is one step closer to being home to a major cannabis production facility. During Wednesday’s Ulster County Industrial Development Agency (IDA) meeting, the board voted 7-0 to approve a...

Cannabis Industry Picking Up Steam with $70 Billion Valuation by 2028

Cannabis Industry Picking Up Steam with $70 Billion Valuation by 2028 A maturing cannabis industry has the potential for enormous growth — but only if growers, processors and retailers can minimize threats to their profitability and stability. The cannabis industry is...

Nearly $1 Million in Cannabis Sales in NJ Every Day

Nearly $1 Million in Cannabis Sales in NJ Every Day One month into existence, New Jersey’s recreational marijuana market has done $24 million in sales and regulators on Tuesday voted to grant permits to nearly a dozen new recreational cannabis retailers in their first...

Rhode Island to Legalize Recreational Cannabis

Rhode Island to Legalize Recreational Cannabis Rhode Island’s governor is signing legislation Wednesday to legalize and regulate recreational cannabis in the state. Democratic Gov. Dan McKee scheduled a bill signing ceremony at the State House for Wednesday afternoon...

5 Things You Should Know Before Using Cannabis Concentrates

5 Things You Should Know Before Using Cannabis Concentrates Among the various forms of marijuana, cannabis concentrates are the ones that have been in existence for a long time but have gained attention in the last few decades. Also known as dabs, concentrates are a...

ROMJF Announces New Cannabis Export Capabilities, Stock Jumps

ROMJF Announces New Cannabis Export Capabilities, Stock Jumps Rubicon Organics (OTC: ROMJF) announced today that its’ Delta Facility had received its CUMCS Equivalency IMC-G.A.P. certification, the leading certification standard for medical cannabis cultivation,...

NJ Operator to turn Church into 30,000SF Cannabis Facility

NJ Operator to turn Church into 30,000SF Cannabis Facility The planning board hearing on a proposal to convert a vacant church into a facility to grow medical cannabis will continue next month. The first hearing on the proposal by GMNJ Properties, part of...

Got Dividends? Altria Announces $0.90/share this Quarter

Got Dividends? Altria Announces $0.90/share this Quarter Altria Group, Inc. (NYSE: MO) held its 2022 Annual Meeting of Shareholders (Annual Meeting) today. During the Annual Meeting, Billy Gifford, Altria’s Chief Executive Officer, summarized our full-year 2021 and...

Two NM Tribes Poised to Sell Recreational Cannabis

Two NM Tribes Poised to Sell Recreational Cannabis Two New Mexico tribes have signed an agreement with state officials recognizing the tribe’s authority to collect taxes on sales of cannabis products. The move announced by state officials Thursday after it was signed...